TAME (Transfer of Abnormal and Mosaic Embryos)

This clinical research study will investigate the pregnancy outcomes of transferring abnormal and mosaic embryos. Mosaic embryos have both chromosomally normal and chromosomally abnormal cells. Sometimes, these mosaic or abnormal embryos are the only option available for in-vitro fertilization treatments. This is the first study to look at the pregnancy outcomes after transfer of chromosomally abnormal embryos in humans.

Who is eligible to participate?

  • Any patient desiring transfer of abnormal and mosaic embryos after PGT-A (preimplantation genetic testing for aneuploidy, or the presence of an abnormal number of chromosomes in a cell).
  • Patients must first undergo counseling with our genetic counselor and pass a mandatory 30-day waiting period.

Study participation involves:

  • Follow pregnancy outcome after transfer of abnormal or mosaic embryos (three months, two years, five years).
  • Patients are recommended but not required to undergo invasive prenatal testing (amniocentesis) during pregnancy.
  • Patients are asked to donate placenta and cord blood at delivery for banking.

For more information, please contact:

Fertility and Reproductive Health logo